PL2427416T3 - Podstawione związki aromatyczne i ich zastosowania farmaceutyczne - Google Patents

Podstawione związki aromatyczne i ich zastosowania farmaceutyczne

Info

Publication number
PL2427416T3
PL2427416T3 PL10771933.8T PL10771933T PL2427416T3 PL 2427416 T3 PL2427416 T3 PL 2427416T3 PL 10771933 T PL10771933 T PL 10771933T PL 2427416 T3 PL2427416 T3 PL 2427416T3
Authority
PL
Poland
Prior art keywords
aromatic compounds
substituted aromatic
pharmaceutical applications
pharmaceutical
applications
Prior art date
Application number
PL10771933.8T
Other languages
English (en)
Polish (pl)
Inventor
Boulos Zacharie
Christopher Penney
Lyne Gagnon
Jean-François Bienvenu
Valérie Perron
Brigitte Grouix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2427416T3 publication Critical patent/PL2427416T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/39—Unsaturated compounds containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
PL10771933.8T 2009-05-04 2010-05-03 Podstawione związki aromatyczne i ich zastosowania farmaceutyczne PL2427416T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17523509P 2009-05-04 2009-05-04

Publications (1)

Publication Number Publication Date
PL2427416T3 true PL2427416T3 (pl) 2016-09-30

Family

ID=43049874

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10771933.8T PL2427416T3 (pl) 2009-05-04 2010-05-03 Podstawione związki aromatyczne i ich zastosowania farmaceutyczne

Country Status (21)

Country Link
US (4) US8927765B2 (https=)
EP (1) EP2427416B1 (https=)
JP (2) JP2012526052A (https=)
KR (2) KR20120024696A (https=)
CN (1) CN102438975B (https=)
AU (1) AU2010244930B2 (https=)
BR (1) BRPI1015124B8 (https=)
CA (1) CA2761018C (https=)
DK (1) DK2427416T3 (https=)
EA (1) EA022445B1 (https=)
ES (1) ES2575100T3 (https=)
HU (1) HUE029126T2 (https=)
IL (1) IL216006A (https=)
MX (1) MX2011011757A (https=)
MY (1) MY156780A (https=)
NZ (1) NZ595978A (https=)
PL (1) PL2427416T3 (https=)
PT (1) PT2427416E (https=)
SG (1) SG175855A1 (https=)
TW (1) TWI485134B (https=)
WO (1) WO2010127440A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011756A (es) * 2009-05-04 2012-01-25 Prometic Biosciences Inc Sales de acido 3-pentilfenilacetico y usos farmaceuticos.
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
MX365807B (es) * 2010-10-27 2019-06-14 Prometic Pharma Smt Ltd Compuestos y composiciones para el tratamiento del cáncer.
CA2816094A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
CA2930584A1 (en) 2013-11-15 2015-05-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
ES2785317T3 (es) * 2014-10-10 2020-10-06 Liminal Biosciences Ltd Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis
KR20170072352A (ko) * 2014-11-12 2017-06-26 프로메틱 파마 에스엠티 리미티드 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물
AU2016262572B2 (en) 2015-05-14 2020-04-30 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
EP3793546B1 (en) 2018-05-17 2025-11-19 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN108997202A (zh) * 2018-07-10 2018-12-14 湖南华腾制药有限公司 一种（5-三氟甲基-吡啶-2-基）-乙酸盐的制备方法
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
WO2020113340A1 (en) * 2018-12-05 2020-06-11 Liminal Biosciences Limited Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome
EP4051659B1 (en) * 2019-10-31 2026-01-28 Assia Chemical Industries Ltd. Solid state forms of fezagepras and process for preparation thereof
CN115974773B (zh) * 2022-12-30 2024-07-02 广东省科学院生物与医学工程研究所 甘蔗内生真菌所产的化合物及其在抑菌和抗氧化中的应用
WO2024217515A1 (zh) * 2023-04-19 2024-10-24 上海复宏汉霖生物技术股份有限公司 一种杂环取代的芳香化合物、其制备方法及用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2489348A (en) * 1947-01-15 1949-11-29 Hoffmann La Roche Production of arylacetic acids and amides
US2618645A (en) * 1948-11-12 1952-11-18 Bowles Albert Frank Organic mercurials
GB971700A (en) * 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US4021478A (en) * 1972-07-13 1977-05-03 The Upjohn Company Preparation of carboxylic acids from glycidonitriles with ionic lewis acids
GB1465219A (en) * 1975-02-25 1977-02-23 Juste Sa Process for the preparation of a phenyl alkonoic acid and its salts
JPS52107837A (en) * 1976-03-05 1977-09-09 Ricoh Co Ltd Wet type electrostatic development material
NL7709681A (nl) * 1976-09-08 1978-03-10 Sandoz Ag Werkwijzen voor het bereiden en toepassen van fenylazijnzuurderivaten.
US4264582A (en) * 1978-07-31 1981-04-28 The Procter & Gamble Company Isobutylphenylacetate anti-inflammatory composition
JPS5656899A (en) * 1979-10-17 1981-05-19 Pilot Pen Co Ltd:The Recording material
FR2497524B1 (https=) 1981-01-07 1985-12-13 Rhone Poulenc Spec Chim
JPS5855469A (ja) * 1981-09-25 1983-04-01 Sumitomo Chem Co Ltd イソシアヌル酸誘導体、その製造方法およびこれを有効成分とする有機物質用安定剤
US4482439A (en) * 1984-04-05 1984-11-13 Reilly Tar & Chemical Corp. Electrochemical oxidation of pyridine bases
EP0268907A3 (en) 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
JPS63236519A (ja) * 1987-03-24 1988-10-03 Ube Ind Ltd 有害廃ガスの処理方法
CA2004028C (en) * 1988-12-08 1998-09-22 Motoki Torizuka Condensed benzene derivative
IE70430B1 (en) * 1990-02-13 1996-11-27 Lonza Ag Microbiological oxidation of methyl groups in heterocyclic compounds
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
GB9200689D0 (en) * 1992-01-14 1992-03-11 Rhone Poulenc Agriculture New compositions of matter
US5366996A (en) 1992-12-07 1994-11-22 Elford Howard L Method of treating hemoglobinopathies
IT1270846B (it) 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US20060074063A1 (en) 1995-12-29 2006-04-06 Fernandez-Pol Jose A Pharmacological agent and method of treatment
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
JPH11343283A (ja) * 1998-05-29 1999-12-14 Koei Chem Co Ltd ピリジンカルボン酸の製造法
EP1200460A1 (en) * 1999-07-15 2002-05-02 Eli Lilly And Company Pseudomycin n-acyl side-chain analogs
WO2001074487A1 (en) * 2000-04-04 2001-10-11 Daicel Chemical Industries, Ltd. Method of separating imide compound
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
BRPI0616463A2 (pt) * 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
US20100010002A1 (en) 2006-09-01 2010-01-14 Piramal Life Sciences Limited Anticancer use of caffeic acid and its derivatives
ES2400163T3 (es) * 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
US8598208B2 (en) * 2007-08-17 2013-12-03 Actelion Pharmaceuticals Ltd. Pyridine derivatives as S1P1/EDG1 receptor modulators
ZA200801666B (en) * 2007-09-29 2009-01-28 Merck & Co Inc Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2009055932A1 (en) 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
CN101878028A (zh) 2007-11-02 2010-11-03 普罗米蒂克生物科学公司 作为肾保护剂的中链长度脂肪酸和甘油酯
NZ586249A (en) 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
MX2011011756A (es) * 2009-05-04 2012-01-25 Prometic Biosciences Inc Sales de acido 3-pentilfenilacetico y usos farmaceuticos.

Also Published As

Publication number Publication date
JP2012526052A (ja) 2012-10-25
EA201171350A1 (ru) 2012-05-30
US20120088784A1 (en) 2012-04-12
JP5815829B2 (ja) 2015-11-17
US10815183B2 (en) 2020-10-27
EP2427416A1 (en) 2012-03-14
HUE029126T2 (en) 2017-02-28
MY156780A (en) 2016-03-31
AU2010244930A1 (en) 2011-11-17
TWI485134B (zh) 2015-05-21
WO2010127440A1 (en) 2010-11-11
CN102438975B (zh) 2015-12-16
US8927765B2 (en) 2015-01-06
ES2575100T3 (es) 2016-06-24
US20210002202A1 (en) 2021-01-07
IL216006A0 (en) 2012-01-31
EP2427416A4 (en) 2012-10-03
US20150094372A1 (en) 2015-04-02
CA2761018C (en) 2018-03-20
SG175855A1 (en) 2011-12-29
AU2010244930B2 (en) 2016-07-28
NZ595978A (en) 2013-11-29
US20180162799A1 (en) 2018-06-14
CN102438975A (zh) 2012-05-02
CA2761018A1 (en) 2010-11-11
US9938221B2 (en) 2018-04-10
KR20120024696A (ko) 2012-03-14
TW201043601A (en) 2010-12-16
PT2427416E (pt) 2016-06-15
KR20180010332A (ko) 2018-01-30
MX2011011757A (es) 2012-01-25
JP2015061852A (ja) 2015-04-02
BRPI1015124A2 (pt) 2016-04-12
HK1169645A1 (zh) 2013-02-01
KR101923354B1 (ko) 2018-11-28
IL216006A (en) 2015-03-31
EA022445B1 (ru) 2016-01-29
BRPI1015124B8 (pt) 2021-05-25
EP2427416B1 (en) 2016-03-09
BRPI1015124B1 (pt) 2021-02-23
DK2427416T3 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
PL2427416T3 (pl) Podstawione związki aromatyczne i ich zastosowania farmaceutyczne
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
SMT201700008B (it) Composizione farmaceutica
SMT201600350B (it) Composizioni farmaceutiche
PT2448582T (pt) Compostos e composições terapêuticas
SMT201400069B (it) Formulazione farmaceutica
BRPI0920521A2 (pt) combinação farmacêutica
BRPI1012539A2 (pt) composições farmacêuticas
BRPI0924137A2 (pt) composição farmacêutica sólida compreendendo amlodipina e losartan com melhor estabilidade
BRPI1007894A8 (pt) dispositivos de envio de medicamento
BRPI1007907A2 (pt) dispositivos de envio de medicamento
DK3246018T3 (da) Farmaceutisk sammensætning
SMT201700095B (is) Composizioni farmaceutiche per inalazione
EP2451274A4 (en) Pharmaceutical compositions
BRPI1015939A2 (pt) composição farmacêutica
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
EE201300005A (et) Ravimkoostis
IT1394400B1 (it) Composizioni farmaceutiche
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0922653A2 (pt) preparação farmacêutica
CO6801722A2 (es) Composiciones farmacéuticas
DK2271618T3 (da) Farmaceutiske forbindelser
BR112012000383A2 (pt) composições farmacêuticas e formas sólidas